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Abstract 
Background: Several studies in animal models demonstrated that obligate and facultative anaerobic bacteria of the 
genera Bifidobacterium, Salmonella, or Clostridium specifically colonize solid tumors. Consequently, these and other 
bacteria are discussed as live vectors to deliver therapeutic genes to inhibit tumor growth. Therapeutic approaches for 
cancer treatment using anaerobic bacteria have been investigated in different mouse models. In the present study, 
solid three-dimensional (3D) multicellular tumor spheroids (MCTS) of the colorectal adenocarcinoma cell line HT-29 
were generated and tested for their potential to study prodrug-converting enzyme therapies using bacterial vectors 
in vitro.
Results: HT-29 MCTS resembled solid tumors displaying all relevant features with an outer zone of proliferating cells 
and hypoxic and apoptotic regions in the core. Upon incubation with HT-29 MCTS, Bifidobacterium bifidum S17 and 
Salmonella typhimurium YB1 selectively localized, survived and replicated in hypoxic areas inside MCTS. Furthermore, 
spores of the obligate anaerobe Clostridium sporogenes germinated in these hypoxic areas. To further evaluate the 
potential of MCTS to investigate therapeutic approaches using bacteria as gene delivery vectors, recombinant bifido-
bacteria expressing prodrug-converting enzymes were used. Expression of a secreted cytosine deaminase in combi-
nation with 5-fluorocytosine had no effect on growth of MCTS due to an intrinsic resistance of HT-29 cells to 5-fluo-
rouracil, i.e. the converted drug. However, a combination of the prodrug CB1954 and a strain expressing a secreted 
chromate reductase effectively inhibited MCTS growth.
Conclusions: Collectively, the presented results indicate that MCTS are a suitable and reliable model to investigate 
live bacteria as gene delivery vectors for cancer therapy in vitro.
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Background
Solid tumors are characterized by hypoxic and necrotic 
areas, which are the result of high metabolic activity of 
tumor tissue and concomitant lack of oxygen supply due 
to insufficient vasculature [1, 2]. Hypoxic areas of solid 
tumors have an increased resistance to chemotherapy 
and radiation compared to better oxygenated tumor 
tissue [3–7]. This has fuelled the search for alternative 
or supplementary therapeutic strategies. One promising 
approach is the use of bacterial vectors for expression 
of therapeutic genes directly in tumor tissue. Different 
bacterial species including Escherichia coli [8, 9] and Lis-
teria monocytogenes [10, 11] were shown to selectively 
colonize tumors in various animal models. The most fre-
quently investigated bacterial gene delivery systems to 
target solid tumors are, however, facultative or obligate 
anaerobes of the genera Salmonella, Clostridium, and 
Bifidobacterium (reviewed in [12–15]).
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Bifidobacteria are Gram-positive, obligate anaerobic 
bacteria of the normal human intestinal microbiota. Sev-
eral studies in animal models have shown that bifidobac-
teria selectively colonize and replicate in solid tumors 
following oral, intravenous, or intratumoral application 
[16, 17]. Due to their non-pathogenic nature and broad 
use as probiotics, bifidobacteria are promising candidates 
as live vectors for delivery and expression of therapeutic 
genes to inhibit tumor growth. However, most bifido-
bacteria are highly resistant to genetic manipulation and 
only a very limited number of strains have been modified 
to express genes relevant for tumor therapy [18–20].
Another group of Gram-positive, strictly anaerobic 
bacteria widely used for tumor targeting strategies are 
spore-forming Clostridium sp. [21, 22]. In early studies, 
clostridia were mainly used as tumor therapeutics based 
on their oncolytic activity (reviewed in [14, 22]). How-
ever, their oncolytic effect was limited to large tumors 
with extensive and strictly hypoxic areas, tumor regres-
sion was incomplete and experimental animals died from 
clostridial toxins [14]. Consequently, this problem was 
addressed by generation of attenuated or non-pathogenic 
strains [23–25]. A major advantage of clostridia is that 
these microorganisms are able to form spores, which are 
immunologically inert and can be administered safely by 
intravenous injection [22, 26]. Spores of various Clostrid-
ium sp. were shown to selectively germinate in tumors 
and vegetative cells are non-viable in other, more oxygen-
ated tissues [22]. These features make spores an attractive 
alternative for administration of bacterial gene vectors 
to tumor patients. A clinical phase I safety study utiliz-
ing Clostridium novyi-NT spores has been performed in 
patients with various treatment-refractory solid tumor 
malignancies [27]. The non-toxic C. novyi-NT strain 
was generated by inactivation of the phage carrying the 
lethal C. novyi toxin [25]. In animal experiments, a single 
intravenous injection of C. novyi-NT spores resulted in 
efficient colonization of tumors and caused tumor regres-
sion. Moreover, tumors did not recur in approximately 
30 % of the animals [25, 28].
Similarly, facultative anaerobic Salmonella sp. were 
shown to colonize solid tumors [29, 30]. Various recom-
binant Salmonella typhimurium strains have been gener-
ated for different therapeutic strategies, e.g. expression of 
PCEs, immunomodulatory molecules or bacterial toxins 
(reviewed in [29, 30]). Additionally, several attempts were 
made to improve tumor colonization of S. typhimurium 
and to reduce effects of this human pathogen on normal 
tissues [31]. For example, deletion of msbB, whose gene 
product is involved in myristoylation of lipid A, results 
in attenuated virulence and a reduced inflammatory 
response [32]. Tumor-specificity was improved by gen-
eration of mutant strains with metabolic defects that can 
be complemented by nutrients specifically available in 
tumors. To this end, genes such as aroA and purI, which 
encode for crucial steps in purine and amino acid bio-
synthesis, were targets for the generation of auxotrophic 
mutants of S. typhimurium [33–35].
Based on the attenuated vaccine strain S. typhimurium 
SL7207, which carries an inactivated aroA gene [33], the 
“obligate” anaerobic S. typhimurium YB1 was generated 
[36]. S. typhimurium YB1 expresses an RNA molecule 
complementary to the asd mRNA exclusively under 
aerobic conditions. This silences asd expression by an 
anti-sense RNA mechanism during aerobic growth. The 
asd gene encodes for an enzyme required for biosynthe-
sis of diaminopimelic acid (DAP), which is an essential 
component of the bacterial cell wall. In consequence, S. 
typhimurium YB1 is auxotrophic for DAP under aero-
bic conditions but is able to grow in the absence of DAP 
under anaerobic conditions when the anti-sense RNA 
is not expressed. The result is an attenuated strain that 
shows improved colonization and survival in hypoxic 
areas of tumors but not in other, more oxygenated organs 
of mice [36].
A widely used in  vitro model system in preclinical 
cancer research are three-dimensional (3D) spherical 
cell aggregates, so-called multicellular tumor spheroids 
(MCTS), which are formed by a wide range of tumor cell 
lines when cultured under appropriate conditions [37, 
38]. These MCTS display characteristic features of solid 
tumors including different zones of proliferating, apop-
totic, and necrotic cells and an oxygen gradient with 
hypoxic areas in the core [3, 37–39]. Besides the physi-
ological parameters, MCTS also more closely resemble 
the global expression profiles of tumor biopsies than 
classical 2D cell cultures [40, 41]. Based on these proper-
ties, MCTS grown in vitro are increasingly used for drug 
discovery and pharmacokinetic and pharmacodynamic 
studies [37–39, 42].
The objective of the presented study was to evaluate 
the potential of MCTS as an in  vitro model system for 
preclinical investigation of therapeutic strategies to treat 
cancer using anaerobic bacteria as gene delivery vectors.
Results
Characterization of MCTS of the colorectal 
adenocarcinoma cell line HT‑29
Previous studies have shown that different bacteria are 
able to selectively colonize subcutaneous tumors in mice 
[16, 17]. In order to investigate bacterial tumor targeting 
in  vitro, MCTS of the colorectal cancer cell line HT-29 
were established as a 3D model for solid tumors. For the 
generation of MCTS, HT-29 cells were grown in ultra-
low attachment cell culture plates. Over a 14-day period, 
MCTS steadily increased in size (data not shown) and 
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reached a diameter of 500–1000 µm. HT-29 MCTS dis-
played an intense purple hematoxylin staining in the 
outer layers of the MCTS, which gradually fainted into 
a pink eosin staining towards the core (Additional file 1: 
Figure S1A). The inner core of MCTS completely lacked 
fixable structures. Moreover, HT-29 MCTS were charac-
terized by hypoxic areas inside MCTS starting approxi-
mately 100  µm below the outer surface and apoptotic 
cells appeared another 10–20  µm further towards the 
core (Additional file  1: Figure S1B). Proliferating tumor 
cells were observed exclusively on the outermost 100 µm 
in the area where actin staining indicates an intact 
cytoskeleton (Additional file 1: Figure S1C).
Localization and survival of B. bifidum S17 in MCTS
Since MCTS display hypoxic areas similar to those 
observed in tumors in vivo, the ability of obligate anaero-
bic bifidobacteria to colonize MCTS in vitro was tested. 
B. bifidum S17 or fluorescent derivatives were incubated 
with MCTS for 48  h. In cryosections of these MCTS, 
B. bifidum S17 localized predominantly in the core of 
MCTS and this signal co-localized with hypoxic areas 
(Fig.  1a) and the necrotic regions of MCTS inside the 
apoptotic areas (Fig. 1b). In higher magnification images, 
individual, rod-shaped, red-fluorescent B. bifidum S17/
pVG-mCherry could be visualized around Hoechst-
stained cell nuclei indicating a close association of bacte-
ria with tumor cells (Fig. 1c).
In order to check if B. bifidum S17 is able to reach the 
core of MCTS in a viable state and survive in this niche 
for prolonged periods, experiments were repeated and 
viable bacteria inside MCTS were quantified for up to 
72  h following infection. Indeed, the number of viable 
B. bifidum S17 remained more or less constant through-
out the experiment (Fig. 1d). By contrast, in plain culture 
media, i.e. in the absence of MCTS, viable B. bifidum 






















Fig. 1 Localization and survival of B. bifidum S17 in MCTS. HT-29 MCTS were incubated with B. bifidum S17/pVG-GFP (a S17, green) or B. bifidum S17/
pVG-mCherry (b, c S17, red) for 48 h. Cryosections of MCTS were stained for hypoxia (a Hypoxyprobe-Red549, red) or apoptosis (b TUNEL, green). 
Nuclei were stained with Hoechst. Images were acquired with a ×10 (in a, b scale bars 100 µm; all three fluorescence channels are shown plus the 
merged image in the lower right panel) or ×40 (in c scale bar 20 µm) objective. The inset in the upper right corner of c is a digital zoom on the image 
part marked with a white box. d Viable bacteria of B. bifidum S17 WT in HT-29 MCTS were determined at different time points after inoculation. 
As controls (medium), bacteria were incubated under identical conditions in the absence of MCTS. For each strain, time-point and condition, six 
tumors were infected and combined for preparation of tumor lysates. Values are colony-forming units (CFU) per mL lysate and are mean ± standard 
error of the mean (SEM) of three tumor lysates infected with independent bacterial cultures. Statistical analysis was performed for each time-point 
using Student’s t test (***P < 0.001)
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S17 counts dropped by more than 4 orders of magni-
tude within the first 24 h and were below the detection 
limit after 72 h. Control experiments were performed by 
incubation of B. bifidum S17 with monolayers of HT-29 
cells. As observed for plain culture media, viable counts 
dropped below the detection limit within 72  h (data 
not shown) demonstrating that presence of HT-29 cells 
alone is not sufficient but instead formation of MCTS is 
required to maintain viability.
Colonization of HT‑29 MCTS by other tumor targeting 
bacteria
Salmonella sp. are the most frequently used bacteria in 
tumor targeting studies. One example is S. typhimu-
rium YB1, a strain that was rendered obligate anaerobic 
to improve selective localization and survival in hypoxic 
tumor tissue [36]. Following co-incubation, S. typh-
imurium YB1 was mainly present in the core of MCTS 
although some bacteria were also detected on the outer 
surface of the MCTS (Fig.  2a). Moreover, bacteria were 
present mainly in areas that also stained positive for 
hypoxia and apoptosis (Fig. 2a–c). Experiments to quan-
tify viable bacteria in MCTS showed that S. typhimurium 
YB1 is able to survive inside tumor spheroids for at least 
72 h (Fig. 2d). In fact, after a slight decrease during the 
first 24  h, viable S. typhimurium YB1 increased tenfold 
over the next 48  h indicating replication of S. typhimu-
rium YB1 in MCTS. Over the same period, the number of 
viable bacteria in controls (i.e. bacteria in medium with-
out MCTS) decreased by about 4 orders of magnitude.
Another group of bacteria frequently used as gene 
delivery vector in cancer therapy are spore-forming 
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Fig. 2 Localization and survival of S. typhimurium YB1 in MCTS. HT-29 MCTS were incubated with S. typhimurium YB1 (YB1, green). After 48 h, MCTS 
cryosections were stained for S. typhimurium (a, c Alexa Fluor® 488-conjugated secondary antibody, green; b Alexa Fluor® 555-conjugated second-
ary antibody, red) and hypoxia (a, c Hypoxyprobe, red) or apoptosis (b TUNEL, green). Nuclei were stained with Hoechst (blue). Images were acquired 
with a ×10 (a, b scale bars 100 µm; all three fluorescence channels are shown plus the merged image in the lower right panel) or ×100 (in c scale 
bar 10 µm) objective. The image in c is acquired at a location inside the hypoxic area of an MCTS. The inset in the upper right corner of c is a digital 
zoom on the image part marked with a white box. d Viable bacteria of S. typhimurium YB1 in HT-29 MCTS at different time points after inoculation. 
As controls (medium), bacteria were incubated under identical conditions in the absence of MCTS. For each strain, time-point and condition, six 
tumours were infected and combined for preparation of tumour lysates. Values are colony-forming units (CFU) per mL lysate and are mean ± SEM 
of three tumour lysates infected with independent bacterial cultures (in some cases, error bars are smaller that graph symbols). Statistical analysis 
was performed using Student’s t test (*P < 0.05; **P < 0.01; ***P < 0.001)
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clostridia [22]. In order to test the utility of MCTS to 
study tumor targeting using clostridial spores, MCTS 
were incubated for 7 days with a pure spore preparation 
of C. sporogenes NCIMB 10696. Clostridial spores accu-
mulated exclusively inside MCTS starting about 100 µm 
underneath the outer surface (Fig.  3a), which correlates 
with the beginning of hypoxia (Additional file  1: Figure 
S1B). Upon closer examination, structures that stained 
positive for Hoechst were observed in areas of stained 
spores (Fig.  3b). These structures clearly differed mor-
phologically from cell nuclei and had the size and shape 
of bacilli, i.e. the vegetative form of C. sporogenes (Fig. 3c) 
suggesting germination of spores.
Generation of HT‑29/GFP MCTS
In order to test potential therapeutic strategies using 
bacteria as gene delivery vectors, fluorescent MCTS 
were generated. For this purpose, HT-29 cells were sta-
bly transfected with pEGFP-N3 (Clontech Laboratories, 
USA; Additional file  2: Materials S2). HT-29/EGFP4, a 
clone exhibiting stable, bright fluorescence, absence of 
EGFP-negative cells (Additional file  3: Figure S2A) and 
identical growth characteristics as the parental cell line 
(data not shown), was selected for further experiments. 
After 14  days of incubation, MCTS of HT-29/EGFP4 
cells had the same size as those of the parental cell line 
but showed a uniform green fluorescent label throughout 
the MCTS (Additional file 3: Figure S2B). To test if strate-
gies to inhibit growth of MCTS can be monitored using 
this system, mature HT-29/EGFP4 MCTS were treated 
with staurosporine. Fluorescence intensity of untreated 
HT-29/EGFP4 MCTS increased by 70–80 % over a 96 h 
period. By contrast, HT-29/EGFP4 MCTS treated with 
30 or 300 nM staurosporine showed no increase in EGFP 
fluorescence (Additional file  3: Figure S2C) indicating 
efficient inhibition of MCTS growth. This suggests that 
HT-29/EGFP4 MCTS are a valid model to study thera-
peutic approaches to inhibit tumor growth.
Evaluation of PCE strategies in HT‑29/GFP MCTS
In a previous study, we generated B. bifidum S17/pAO-
S0_CD, a strain expressing a secreted derivative of the 
E. coli cytosine deaminase [43]. This bacterial enzyme is 
not present in mammalian cells and converts the non-
toxic prodrug 5-FC to the potent cytostatic compound 
5-FU, which inhibits DNA synthesis. The potential of 
B. bifidum S17/pAO-S0_CD in combination with 5-FC 
to inhibit tumor growth in  vitro was analyzed using 
HT-29/EGFP4 MCTS (Fig. 4a). Fluorescence of untreated 
MCTS increased by approx. 60  % over the 96  h moni-
tored and staurosporine-treated control MCTS showed 
significantly decreased EGFP intensity. Neither B. bifi-
dum S17/pAO-S0_CD, nor 5-FC, or the combination of 
Fig. 3 Germination of C. sporogenes spores in MCTS. HT-29 MCTS 
were infected with 1 × 103 spores and incubated for 7 days. Cryosec-
tions of MCTS were then stained for spores (FITC-conjugated antise-
rum, green). Nuclei and DNA of vegetative bacterial cells were stained 
with Hoechst (blue). Images were acquired with a ×10 (in a scale bar 
100 µm), or ×100 (in b, c scale bars 10 µm) objective. Higher mag-
nification images in b, c are acquired at locations inside the hypoxic 
area of MCTS. The inset in the upper right corner of c is a digital zoom 
on the image part marked with a white box. Images are composite of 
both fluorescence channels and one representative image of three 
independent experiments is shown
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both, resulted in a reduction of the fluorescence intensity 
below control levels.
One possible explanation for the lack of an effect on 
MCTS by the combination of B. bifidum S17/pAO-
S0_CD and 5-FC could be an intrinsic resistance of the 
HT-29 cell line to 5-FU treatment, as reported for differ-
ent colon cancer cells [44, 45]. To test this hypothesis, the 
pure compound 5-FU was added to HT29/EGFP4 MCTS. 
Interestingly, none of the tested concentrations of 5-FU 
was able to inhibit the increase in EGFP intensity during 
MCTS growth, indicating that the clone of HT-29 cells 
used to generate MCTS was resistant to 5-FU (Fig. 4b).
To test a second PCE strategy, pMgapS6C (Fig.  5a) 
was generated and transformed into B. bifidum S17. The 
recombinant strain B. bifidum S17/pMgapS6C expresses 
a secreted chromate reductase. This enzyme belongs to 
the family of nitroreductases and converts the prodrug 
CB1954 to hydroxylamines, which intercalate into DNA 
and efficiently inhibit tumor cell growth [46]. Culture 
supernatants of B. bifidum S17/pMgapS6C contained 
highly increased nitroreductase activity compared to the 
control strain (Fig. 5b).
Incubation with B. bifidum S17/pMgapS6C and CB1954 
resulted in efficient growth inhibition of HT-29/EGFP4 
MCTS compared to the negative controls. The EGFP sig-
nal of MCTS treated with B. bifidum S17/pMgapS6C 
or CB1954 alone did not differ from untreated controls. 
However, fluorescence of MCTS treated with a combi-
nation with B. bifidum S17/pMgapS6C and CB1954 was 
reduced significantly and was comparable to that observed 
with staurosporine treatment (Fig. 5c). This indicates effi-
cient growth inhibition of HT-29/EGFP4 MCTS upon 
treatment with the recombinant strain and the prodrug.
Discussion
Delivery of therapeutic genes by anaerobic bacteria is an 
attractive alternative or supplementary strategy in cancer 
treatment [12–15]. The vast majority of studies on bac-
terial tumor targeting have been performed in mouse 
models. In the present study, 3D MCTS of the colorec-
tal adenocarcinoma cell line HT-29 were evaluated as a 
model system to investigate bacterial tumor targeting 
in vitro.
HT-29 MCTS displayed (patho)physiologically rel-
evant features of solid tumors. Size and organization of 
these MCTS into a proliferating outer zone and increas-
ing hypoxia, apoptosis and necrosis towards the core 
are in line with previous reports [37, 38]. The presented 
data provides direct evidence for a selective localiza-
tion of tumor targeting bacteria in hypoxic areas of 3D 
tumor spheroids. B. bifidum S17 derivatives expressing 
the fluorescent proteins GFP or mCherry were detected 
almost exclusively in hypoxic areas of MCTS. S. typh-
imurium YB1 localized preferentially to hypoxic areas of 
MCTS and appeared to proliferate in this niche (Fig. 2). 
Both strains are able to survive at high rates for at least 
72 h in MCTS. By contrast, viable bacteria of both strains 
decreased significantly in controls, i.e. medium without 
MCTS. Slight differences in the viability under these con-
ditions were noted with a more rapid decrease observed 
for B. bifidum S17 compared to S. typhimurium YB1. This 
may be due to the fact that bifidobacteria are obligate 
anaerobes to which presence of oxygen is detrimental. 
S. typhimurium strains are facultative anaerobes, which 
are able to grow without oxygen but prefer growth under 
aerobic conditions. The YB1 strain is genetically modified 
in a way that they are not able to grow in the presence of 
oxygen [36]. However, oxygen is not toxic to YB1 which 
maybe the reason for the better survival of YB1 under cell 
culture conditions.
Bifidobacterium bifidum S17 and S. typhimurium YB1 
were found in slightly different locations of the MCTS. 



























Fig. 4 Effect of B. bifidum S17/pAO-S0_CD and 5-FC on HT-29/EGFP4 
MCTS. a HT-29/EGFP4 MCTS were incubated with B. bifidum S17/
pAO-S0_CD (S17 CD) alone or in combination with 0.25 mg/mL 5-FC 
up to for 96 h. As controls, MCTS were treated with 200 nM stauro-
sporine (stauro), 5-FC, or medium alone (-). b HT-29/EGFP4 MCTS 
were grown in the presence and absence of 0.5 or 0.05 mg/mL 5-FU. 
All MCTS were analyzed for growth by fluorescence measurements 
for 96 h. Fluorescence intensities were normalized to give 100 % for 
each MCTS at the start of the experiment (t = 0 h). Values are relative 
fluorescent units (RFU) per MCTS and are mean ± SEM of three MCTS. 
Results of one representative of three independent experiments are 
shown. Statistical analysis was performed using two-way ANOVA with 
Bonferroni post-test correction for multiple comparisons (***differ-
ence to untreated MCTS significant with adjusted P < 0.001, all other 
comparisons not significant)
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While B. bifidum S17 was detected almost exclusively 
in hypoxic areas of tumors, S. typhimurium YB1 also 
adhered to the outer surface. This might be due to dif-
ferences in the labeling methods. B. bifidum S17 was 
detected by expression of fluorescent proteins. By con-
trast, S. typhimurium YB1 was labeled with a specific 
antibody. Whereas the former method detects only 
intact, metabolically active cells, antibodies stain all 
bacteria including dead or metabolically inactive cells. 
Thus, it is possible that the signal of S. typhimurium YB1 
detected on the outside of MCTS represents non-replica-
tive, inactive, or dead bacteria.
Nevertheless, S. typhimurium YB1 was shown to prolif-
erate in MCTS at later time-points indicating that some 
bacteria, presumably those that reside in hypoxic areas, 
are viable. Similarly, expression of fluorescent proteins by 
B. bifidum S17 and germination of C. sporogenes spores 
in hypoxic areas of MCTS suggest metabolic activity. 
Moreover, germination of spores of strictly anaerobic C. 
sporogenes NCIMB 10696 was observed inside MCTS 
(Fig. 3). This suggests that oxygen levels inside MCTS are 
sufficiently low to support colonization of hypoxic areas 
of HT-29 MCTS by obligate anaerobic bacteria. Thus, the 
presented data confirms previous findings on selective 
colonization of solid tumors by these bacteria in animal 
models [16, 17, 25, 35, 36].
These findings indicate that recombinant, tumor tar-
geting bacteria are likely to express therapeutic genes 
inside MCTS. To test the potential of MCTS for studies 
on therapeutic approaches, derivative of the HT-29 cell 
line stably transfected for constitutive EGFP expression 
was generated. Techniques employing fluorescent labels 
or read-outs are widely used for high-throughput drug 
discovery [47, 48] and EGFP-expressing HT-29 tumor 
spheroids have been generated previously for the high-
throughput screening of pharmacological treatments 
[49]. Proliferation of entire spheroids was measured by 
EGFP fluorescence intensity using a microtiter plate 
reader. This is an easy, reliable and fast measurement. 
While flow cytometry would be a theoretical alternative 
providing quantitative information on the total number 
of cells in spheroids and the fluorescence intensity on the 
single cell level, it bears downsides that are related to the 
spheroid model. For example, spheroids need to be disin-
tegrated to a single cell suspension prior to flow cytom-
etry. In fact, several attempts to reproducibly and reliably 
obtain single cell suspension from HT-29 MCTS by enzy-
matic treatment with or without mechanical disruption 
failed (data not shown) probably due to the tight cell–cell 
adhesion of cells within spheroids. Staurosporine treat-
ment of HT-29/EGFP4 MCTS resulted in a dose-depend-
ent inhibition of the increase in EGFP fluorescence of 
MCTS (Additional file  3: Figure S2C) as reported for 
other cell lines [50] demonstrating the principal feasibil-
ity of HT-29/EGFP4 MCTS to test therapeutic strategies.
To test therapeutic approaches using bacterial gene 
delivery vectors, recombinant strains of B. bifidum S17 
were generated expressing two of the most widely used 
PCEs: cytosine deaminase and chromate reductase. Both 
PCEs have been used successfully in bacterial tumor 






































Fig. 5 Effect of B. bifidum S17/pMgapS6C and CB1954 on HT-29/EGFP4 MCTS. a Vector map of pMgapS6C for expression of a secreted chromate 
reductase in bifidobacteria. b Chromate reductase activity in the supernatants of B. bifidum S17/pMgapS6C (S17/ChrR6) or the empty vector control 
strain B. bifidum S17/pMDY23-Pgap (S17/-). c HT-29/EGFP4 MCTS were incubated with S17/ChrR6 alone or in combination with 100 µM CB1954 
(CB) for up to 96 h. As controls, MCTS were treated with 200 nM staurosporine (stauro), CB1954 (CB) or medium alone (-). Fluorescence intensities 
were normalized to give 100 % for each MCTS at the start of the experiment (t = 0 h). Values are relative fluorescent units (RFU) per MCTS and are 
mean ± SEM of three MCTS. Results of one representative of three independent experiments are shown. Statistical analysis was performed using 
two-way ANOVA with Bonferroni post-test correction for multiple comparisons (***difference to untreated MCTS significant with adjusted P < 0.001, 
all other comparisons not significant)
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targeting studies in animals models [51, 52]. In MCTS, a 
combination of B. bifidum S17/pMgapS6C and CB1954 
was able to inhibit tumor growth (Fig. 5c). By contrast, B. 
bifidum S17/pAO-S0_CD expressing cytosine deaminase 
in combination with the prodrug 5-FC had no effect on 
growth of HT-29 MCTS (Fig.  4a). Further experiments 
revealed that the clone of HT-29 cells used for experi-
ments had an intrinsic resistance to the active compound 
5-FU produced by the PCE (Fig. 4b). Similar observations 
have been published for this and other colon cancer cell 
lines [44, 45].
The vast majority of reports on bacterial tumor-tar-
geting have been performed in mouse models and there 
are very few studies on bacterial tumor targeting using 
3D in vitro models. To our knowledge, there is only one 
study in which tumor spheroids were used to investigate 
the therapeutic effect of a recombinant S. typhimurium 
strain expressing a therapeutic gene [53]. A microfluidic 
tumor model was used to analyze proliferation of differ-
ent E. coli strains in [54]. This system consists of a reac-
tor chamber with a diameter 100  µm connected to two 
outer channels perfused with oxygenated medium by 
pores of 4 µm allowing diffusion of nutrients and oxygen. 
Thus, it probably does not allow for the development of 
extensively hypoxic areas, which in MCTS start not until 
approx. 100  µm below the outer surface. Tumor cylin-
droids, which are derived from MCTS, have been used 
study tumor colonization by S. typhimurium [55–57]. 
Compared to MCTS, both cylindroids and microfluidics 
are technically by far more challenging, require signifi-
cant additional equipment, and are thus not suitable for 
large scale or high throughput screenings.
Conclusions
Collectively, our results demonstrate that MCTS gen-
erated from HT-29 cells are a suitable model system to 
study tumor targeting strategies using obligate anaero-
bic bacteria or their spores in  vitro. A wide range of 
other tumor cell lines have been shown to form similar 
MCTS when cultured appropriately [37–39]. Moreover, 
MCTS can be grown in a high-throughput format [42] 
or developed further into more complex model systems 
offering the opportunity to analyze the molecular cross-
talk between tumor cells and other cell types frequently 
found in tumors such as fibroblasts or immune cells 
[38, 58–60]. This may facilitate research on therapeutic 
approaches beyond PCE strategies, e.g. recombinant bac-
terial vectors expressing defined cytokines that modulate 
the anti-inflammatory phenotype of tumor-associated 
macrophages or activate infiltrating T- or NK-cells.
In conclusion, MCTS have great potential to facilitate 
preclinical investigation of bacterial tumor targeting. 
MCTS allow efficacy testing of existing bacterial vectors, 
the development of new therapeutic strategies involving 
bacterial gene delivery, or oncolytic effects of bacteria 
an in vitro setting before turning to time, cost, and labor 
intensive animal experimentation.
Methods
Bacterial strains and growth conditions
Bifidobacterial strains were grown in Lactobacilli MRS 
medium (Difco) supplemented with 0.5  g/L l-cysteine 
(MRSc) under anaerobic conditions (AnaeroGenTM, 
Oxoid) at 37 °C. For cultivation of B. bifidum S17 deriva-
tives carrying plasmids pVG-mCherry, pVG-GFP, pAO-
S0_CD [43, 61], or pMgapS0C, MRSc was supplemented 
with 100 µg/mL spectinomycin. S. typhimurium YB1 [36] 
was kindly provided by Prof. Jian-Dong Huang (Univer-
sity of Hong Kong) and was grown aerobically at 37 °C in 
DMEM cell culture medium supplemented with 50  µg/
mL DAP and 25  µg/mL chloramphenicol. Clostridium 
sporogenes NCIMB 10696 (NCIMB Ltd., Aberdeen, GB) 
was cultivated anaerobically in 2YT medium containing 
3 % (w/v) tryptone, 2 % (w/v) yeast extract, and 8.7 mM 
sodium thioglycolate.
For generation of C. sporogenes spores, 50 mL medium 
was inoculated and incubated for 2 weeks at 30 °C. Spor-
ulation was monitored microscopically. Spores were 
harvested by centrifugation (30  min, 4  °C, 4500×g) and 
incubated for 30 min in 50 mL 80 % (v/v) ethanol to kill 
any remaining vegetative cells. The pellet was washed 
three times with 50  mL phosphate buffered solution 
(PBS) and suspended in 125 µL PBS. Spores were sepa-
rated by density centrifugation using Percoll®. For this 
purpose 900  µL of filtrated 1.5  M NaCl was added to 
8.1  mL of Percoll® solution (Sigma-Aldrich Chemie 
GmbH, Munich, Germany). 9  mL of this stock solution 
were mixed with 1 mL of 0.15 M NaCl. A gradient was 
prepared by centrifugation using a swinging bucket rotor 
(1 h, room temperature, 4500×g). 125 µL of crude spore 
preparation was applied on top of the gradient followed 
by centrifugation (1 h, room temperature, 1800×g). The 
upper 9 mL of the Percoll®/NaCl gradient were removed 
and the spore sediment was resuspended in 5 mL of PBS 
followed by centrifugation (5 min, RT, 9600×g). The pel-
let was washed three times with PBS and resuspended 
in 1  mL PBS. Absence of vegetative cells was checked 
microscopically. The concentration of colony-forming 
units (CFU) of the spore preparation was determined by 
plating on 2YT agar and cultivation at 30 °C under anaer-
obic conditions.
Cell culture and generation of solid 3D MCTS in vitro
HT-29 colorectal adenocarcinoma cells (ATCC® HTB-
38™) were routinely cultured in DMEM medium sup-
plemented with 5  % (v/v) FCS, 1  % (v/v) non-essential 
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amino acids, and 1 % (v/v) penicillin–streptomycin stock 
solution at 37 °C with 5 % CO2. For generation of MCTS, 
cells were seeded in Ultra-Low Attachment 96-well plates 
(Corning® Costar®) at 1 ×  105  cells in 200  µL medium 
per well. Cells were grown for 14  days with medium 
changed every 2–3 days. MCTS with a diameter of 500–
1000 µm were used for experiments.
To generate green fluorescent MCTS, HT-29 cells were 
transfected with pEGFP-N3 (Clontech Laboratories, 
Inc., USA) and a stable clone HT-29/EGFP4 was selected 
as described in Additional file  2: Materials S2. HT-29/
EGFP4 MCTS were generated using DMEM medium 
without phenol red to avoid interference with EGFP 
fluorescence measurements. Growth of HT-29/EGFP4 
MCTS was monitored by quantification of EGFP fluo-
rescence as an indirect measurement of cell proliferation 
and MCTS size. Fluorescence intensity of HT-29/EGFP4 
MCTS was measured directly in tissue culture plates 
using a Tecan Infinite® M200 multimode reader (Tecan 
Group Ltd., Mannedorf, Switzerland) with excitation at 
477 nm and emission at 507 nm.
Bacterial tumor targeting assays
For survival studies in MCTS, bifidobacteria were inoc-
ulated in 10  mL MRSc supplemented with antibiotics 
as appropriate. S. typhimurium YB1 was inoculated in 
10  mL DMEM containing 50  µg/mL DAP and 25  µg/
mL chloramphenicol. Bacteria were grown anaerobi-
cally (bifidobacteria) or aerobically (S. typhimurium 
YB1) at 37 °C over night (o/N; i.e. for 16 h) to stationary 
growth phase. At this stage, an optical density at 600 nm 
(OD600) of 1 equals approximately 1 × 108 (bifidobacte-
ria) or 1  ×  109 (S. typhimurium YB1) CFU/mL. Bacte-
ria were washed once and resuspended in PBS to a final 
OD600 of 0.1 (bifidobacteria) or 0.01 (S. typhimurium 
YB1). The C. sporogenes spore preparation was adjusted 
to 5 × 105 CFU/mL.
Prior to inoculation, single MCTS in individual wells 
were washed once in DMEM and 180 µL of DMEM sup-
plemented with 60  mM HEPES buffer (without FCS or 
antibiotics) were added. Aliquots of 20 µL of the bacte-
rial suspensions or spore stocks were added to individual 
wells resulting in an inoculum of 2 × 107 CFU or 1 × 103 
spores per MCTS. At the indicated time-points after 
infection, six MCTS infected with the same strain were 
combined. Homogenous suspensions of tumor cells were 
prepared by passing through a syringe (0.4 mm) 5 times 
with vortexing between homogenization steps. Bacte-
rial numbers were determined as CFU/mL in the MCTS 
lysates by plating serial ten-fold dilutions in PBS on 
agar plates (bifidobacteria: MRSc agar; S. typhimurium 
YB1: LB agar containing 50  µg/mL DAP after growth 
under standard conditions. For assays with C. sporogenes 
spores, MCTS were infected and incubated for 7  days 
under cell culture conditions. At this stage tumors were 
examined by fluorescence microscopy.
For experiments with recombinant bifidobacteria 
expressing PCEs, MCTS were incubated with 2  ×  107 
CFU. Medium was changed after 72 h of incubation and 
fresh prodrug was added to MCTS.
Microscopic examination of MCTS
Individual MCTS incubated with bacteria or spores 
for the indicated time were embedded in a drop of Tis-
sueTek® O.C.T Compound (Sakura) in a Leica CM3050S 
cryostat and immediately used to prepare cryosections 
(thickness 10–14 µm), which were then dried on Super-
frost™ Plus microscope slides (Fisher Scientific) and fixed 
with 4 % paraformaldehyde/PBS.
Fixed MCTS were stained with hematoxylin/eosin 
(H&E). Hoechst (Life Technologies) was used at 300 nM 
to stain cell nuclei and cytoskeletal actin was stained 
using Alexa Fluor® 488 Phalloidin (Invitrogen). Hypoxy-
probe-Red549 Kit (Hypoxyprobe) was used to stain for 
hypoxic areas and apoptotic cells were stained by TUNEL 
assay (DNA Fragmentation Imaging Kit, Roche). Pro-
liferating cells were visualized by Ki-67 staining using a 
mouse monoclonal antibody (Cat# MA1-80199, Thermo 
Scientific) and goat α-mouse IgG Alexa Fluor® 555 sec-
ondary antibody (Life Technologies). S. typhimurium 
YB1 was stained with a rabbit polyclonal Salmonella 
antiserum (Cat# PA1-7244, Thermo Scientific) and goat 
α-rabbit Alexa Fluor® 488 or 555 secondary antibodies 
(Life Technologies). Clostridial spores were stained with 
polyclonal, FITC-conjugated Clostridia species antibod-
ies (Cat# PA1-73169, Thermo Scientific). In a mix of veg-
etative C. sporogenes cells only spores were stained by 
the antibody while DNA of vegetative cells was stained 
by Hoechst demonstrating specificity of the antibody for 
spores.
Microscopic analysis was performed with an Axio 
Observer.Z1 microscope (Zeiss) using Zen soft-
ware. The following filter sets were used for fluores-
cence microscopy: 49 (excitation at 365  ±  10  nm, 
emission at 445  ±  50  nm) for Hoechst, 38HE (excita-
tion at 470 ± 40 nm, emission at 525 ± 50 nm) for GFP, 
TUNEL, FITC and Alexa Fluor® 488, and AF (excitation 
at 545 ± 30 nm, emission at 610 ± 75 nm) for mCherry, 
Hypoxyprobe-Red549, and Alexa Fluor® 555.
Cloning of PCE‑expressing B. bifidum S17 strains
Bifidobacterium bifidum S17/pAO-S0_CD expressing a 
secreted cytosine deaminase has been described previ-
ously [43]. A similar construct was devised to generate a 
recombinant B. bifidum S17 strain expressing a secreted 
chromate reductase. For this purpose, the chrR6 gene 
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encoding an artificial nitroreductase created by mutation 
of the E. coli yieF gene, which shows faster enzyme kinet-
ics than its native form, was used [62]. The chrR6 gene was 
codon-optimized for B. bifidum S17 and fused in silico to 
the coding sequence of S6, a signal peptide of B. bifidum 
S17 for efficient protein secretion [43]. The codon-opti-
mised fusion was synthesised by a commercial provider 
(Eurofins Genomics GmbH; Germany) and amplified by 
PCR using primers S6F (3′-GGCCTCGAGATGAAATCA 
CTGATGAAAAAGGTTTTCGC-5′) and ChrR (3′-CCC 
AAGCTTTTAAATTTTCACGCGTTG-5′) to intro-
duce appropriate restriction sites (underlined in primer 
sequences). The obtained PCR product was digested with 
restriction enzymes XhoI and HindIII and ligated to the 
4423  bp fragment of XhoI/HindIII digested pMDY23-
Pgap [63] yielding pMgapS6C, which encodes an exact 
transcriptional fusion of the S6-chrR6 sequence to the 
gap promoter of B. bifidum S17 for strong constitutive 
expression [64].
Following transformation into E. coli, plasmids of spec-
tinomycin resistant colonies were checked for correct 
inserts by PCR. Plasmids of positive clones were verified 
by restriction analysis and Sanger sequencing. A plasmid 
with correct sequences and a mutation-free insert was 
termed pMgapS6C. This plasmid and the empty vector 
control (pMDY23-Pgap) were transformed into B. bifi-
dum S17 as described elsewhere [65]. Chromate reduc-
tase activity was measured in culture supernatants of 
recombinant bifidobacteria grown for 16 h in Reinforced 
Clostridium Medium at 37  °C under anaerobic condi-
tions using a previously described enzymatic assay [66].
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